Results 141 to 150 of about 108,143 (259)

Diffuse Large B-Cell Lymphoma in 2016

Journal of Clinical and Experimental Hematopathology, 2016
openaire   +3 more sources

Primary ovarian diffuse large B-cell lymphoma. [PDF]

BMJ Case Rep
Singh P, Prakash VS, Rathore A, Chowdhary GS, Saraswat M.   +4 more
europepmc   +1 more source

Diffuse Large B-Cell Lymphoma of the Ethmoid Sinus With Orbital Invasion: A Case Report. [PDF]

Cureus
Boualam Y, Sbai A, Benfadil D, Lachkar A.   +3 more
europepmc   +1 more source

Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non‐Hodgkin lymphomas

British Journal of Haematology, EarlyView.
Optical genome mapping (OGM) is feasible on fresh and frozen tissue lymphoma samples and demonstrated its added value for accurate diagnostic classification. OGM surpasses karyotype and FISH in refining diagnoses of lymphoma, identifying class‐defining rearrangements along with prognostic markers.
Coura Fall, Agnès Daudignon, Séverine Valmary‐Degano, Julie Mondet, Lucile Bussot, Lysiane Molina, Simon Chevalier, Edouard Bonneville, Pierre Aubert, Sylvie Tondeur, Clémentine Legrand, Jean‐Baptiste Gaillard, Hélène Guermouche, Anouk Emadali, Sylvain Carras, Christine Lefebvre   +15 more
wiley   +1 more source

Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma. [PDF]

Front Immunol
Zhan Z, Li P, Liu Y, Zhen C, Zhang Y, Bai O.   +5 more
europepmc   +1 more source

Current treatment algorithm: diffuse large B cell lymphoma. [PDF]

Blood Cancer J
Ansell SM, Nowakowski GS.
europepmc   +1 more source

Machine learning‐driven investigation on liquid–liquid phase separation‐related prognostic signature in diffuse large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) is the most common aggressive non‐Hodgkin lymphoma and is characterized by substantial heterogeneity. This study aimed to develop a liquid–liquid phase separation (LLPS)‐related prognostic model to improve risk stratification.
Zhen‐Zhong Zhou, Jia‐Chen Lu, Zhao Wang, Rong‐Hui Chen, Hai‐Long Li, Wan‐Ting Chen, Yu‐Ning Deng, Hui‐Juan Zhang, Yu Wang, Xuan‐Ye Zhang, Wei‐Juan Huang, Xiao‐Peng Tian   +11 more
wiley   +1 more source

Neutrophil Elastase as a Prognostic Biomarker and Driver of Tumor Progression in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Zheng X, Wang L, Liu Z, Qiu Y, Lu J, Shu L, Xu C, Zhou M, Miao Y, Cheng Y.   +9 more
europepmc   +1 more source

Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study

British Journal of Haematology, EarlyView.
Summary Early identification of patients at risk of failing first‐line therapy remains a key challenge in primary mediastinal B‐cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL.
L. Ceriani, L. Milan, L. Cascione, A. Di Rocco, I. Kryachok, A. J. Davies, A. Stathis, D. Rossi, P. W. M. Johnson, M. Martelli, E. Zucca   +10 more
wiley   +1 more source

Primary Cardiac Diffuse Large B-Cell Lymphoma: A Diagnostic Pitfall With Overlapping Imaging Features. [PDF]

JACC Case Rep
Ünlügenç H, Yıldız BS, Demir D, Bayraktaroğlu S, Demir E, Özerkan Çakan F, Nalbantgil S.   +6 more
europepmc   +1 more source